Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study
| Autor: | Marie-Christiane Vekemans, Martine Escoffre, Norbert Ifrah, Hervé Dombret, Delphine Rea, Aline Tanguy-Schmidt, Xavier Thomas, Sandrine Hayette, Philippe Rousselot, André Delannoy, Yves Chalandon, Jean-Paul Vernant, Jean-Yves Cahn, Françoise Huguet, Jean-Michel Cayuela |
|---|---|
| Přispěvatelé: | Univers, Transport, Interfaces, Nanostructures, Atmosphère et environnement, Molécules (UMR 6213) (UTINAM), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS), Laboratoire central d'hématologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Biologie Moléculaire, Hospices Civils de Lyon (HCL), Laboratoire d'Hématologie [Purpan], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Hôpital de Jolimont, Haine-Saint-Paul and Cliniques Universitaires St Luc, TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hématologie clinique [Avicenne], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Lymphocyte et cancer, IFR105-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Edouard Herriot [CHU - HCL] |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Male Time Factors medicine.medical_treatment MESH: Piperazines Hematopoietic stem cell transplantation Acute lymphoblastic leukemia MESH: Philadelphia Chromosome Piperazines MESH: Unrelated Donors MESH: Benzamides 0302 clinical medicine hemic and lymphatic diseases Philadelphia Chromosome ddc:616 Philadelphia Chromosome Positive MESH: Middle Aged Stem cell transplantation Age Factors Hematopoietic Stem Cell Transplantation Hematology MESH: Follow-Up Studies Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma MESH: Transplantation Autologous 3. Good health Survival Rate Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality/therapy 030220 oncology & carcinogenesis Benzamides Imatinib Mesylate Female Unrelated Donors medicine.drug Adult medicine.medical_specialty Adolescent MESH: Survival Rate Pyrimidines/administration & dosage/adverse effects Antineoplastic Agents [SDV.CAN]Life Sciences [q-bio]/Cancer Philadelphia chromosome Transplantation Autologous Disease-Free Survival 03 medical and health sciences Internal medicine medicine MESH: Transplantation Homologous Humans Transplantation Homologous Survival rate MESH: Hematopoietic Stem Cell Transplantation MESH: Adolescent MESH: Precursor Cell Lymphoblastic Leukemia-Lymphoma MESH: Age Factors Transplantation MESH: Humans business.industry MESH: Time Factors Imatinib Benzamides/administration & dosage/adverse effects MESH: Adult medicine.disease Piperazines/administration & dosage/adverse effects MESH: Male Surgery Clinical trial Imatinib mesylate Pyrimidines MESH: Pyrimidines MESH: Disease-Free Survival MESH: Antineoplastic Agents Antineoplastic Agents/administration & dosage/adverse effects business MESH: Female 030215 immunology Follow-Up Studies |
| Zdroj: | Biology of Blood and Marrow Transplantation Biology of Blood and Marrow Transplantation, Elsevier, 2013, 19 (1), pp.150-5. ⟨10.1016/j.bbmt.2012.08.021⟩ Biology of Blood and Marrow Transplantation, Vol. 19, No 1 (2013) pp. 150-5 |
| ISSN: | 1083-8791 1523-6536 |
| DOI: | 10.1016/j.bbmt.2012.08.021⟩ |
| Popis: | International audience; We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P = .0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Ph+ ALL in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55 years, including 7 patients in complete molecular response). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect